"Lipoprotein(a)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lipoprotein that resembles the LOW-DENSITY LIPOPROTEINS but with an extra protein moiety, APOPROTEIN (A) also known as APOLIPOPROTEIN (A), linked to APOLIPOPROTEIN B-100 on the LDL by one or two disulfide bonds. High plasma level of lipoprotein (a) is associated with increased risk of atherosclerotic cardiovascular disease.
Descriptor ID |
D017270
|
MeSH Number(s) |
D10.532.350 D12.776.521.400
|
Concept/Terms |
Lipoprotein(a)- Lipoprotein(a)
- Lipoprotein Lp(a)
- Lipoprotein (a)
- Lipoprotein a
|
Below are MeSH descriptors whose meaning is more general than "Lipoprotein(a)".
Below are MeSH descriptors whose meaning is more specific than "Lipoprotein(a)".
This graph shows the total number of publications written about "Lipoprotein(a)" by people in this website by year, and whether "Lipoprotein(a)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 1 | 0 | 1 |
1996 | 1 | 0 | 1 |
1997 | 2 | 0 | 2 |
2000 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2002 | 0 | 2 | 2 |
2004 | 1 | 0 | 1 |
2005 | 0 | 1 | 1 |
2009 | 2 | 0 | 2 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2018 | 3 | 0 | 3 |
2019 | 1 | 1 | 2 |
2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lipoprotein(a)" by people in Profiles.
-
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Curr Atheroscler Rep. 2020 07 25; 22(9):48.
-
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
-
The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature. Cardiovasc Revasc Med. 2020 02; 21(2):200-204.
-
LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. Circulation. 2018 10 23; 138(17):1839-1849.
-
Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. Nat Commun. 2018 07 04; 9(1):2606.
-
Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):673-678.
-
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016 06; 57(6):1086-96.
-
Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther. 2016 Feb; 30(1):101-8.
-
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014 Sep 01; 114(5):711-5.
-
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014 Apr 08; 63(13):1278-1288.